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Introduction
Asthma is a chronic inflammatory disorder of the lower
airway that results in mucus secretion, airway edema and
reversible airway obstruction [1]. These characteristic
features lead to the clinical symptoms of asthma, which
include recurrent episodes of wheezing, breathlessness,
chest tightness and coughing [2]. The pathophysiology of
asthma is not fully elucidated but the current paradigm
involves multiple cell types (ie. eosinophils, neutrophils,
mast cells, T-cells) and their mediators.
T h e  m o s t  r e c e n t  e s t i m a t e s  o f  a s t h m a  p r e v a l e n c e  i n
those over the age of 65 are between 4 and 8%, which may
be an underestimate due to an underdiagnosis of asthma
in the elderly [3]. An increase in morbidity and mortality
and a reduced response to bronchodilators in the emer-
gency department setting have been shown in older asth-
matics compared to their younger counterparts [4-7].
Elderly asthmatics also have a higher rate of severe exac-
erbations, emergency department visits, and hospitaliza-
tions than younger asthmatics [8,9].
Leukotrienes are potent pro-inflammatory lipid media-
tors that have been shown to have a role in asthma [10].
Leukotrienes are a product of arachidonic acid via the 5-
lipoxygenase pathway. Leukotriene B4 (LTB4) is a potent
chemotactic agent and activator of neutrophils and is also
produced mainly by neutrophils. The presence of LTB4 in
the lung results in neutrophil recruitment and activation
leading to superoxide anion generation and cholinergic
airway hyperresponsiveness [11]. The cysteinyl leukot-
rienes (CysLTs), LTC4, LTD4, and LTE4, are known for
their profound effect on the airway, including increased
microvascular permeability and vasodilation, airway
smooth muscle contraction, mucous secretion and
impaired mucociliary clearance [10]. CysLTs are pro-
duced by eosinophils, basophils, mast cells, macrophages
and to a lesser degree by T cells and endothelial cells
[10,12]. Increased CysLT levels have been detected in the
sputum of patients with asthma and have been shown to
correlate with symptom severity [13].
Despite older asthmatics often having more severe dis-
ease and exacerbations, few studies have been done to
characterize their asthma at a cell and/or molecular level.
We have previously shown that functional differences
exist in eosinophils from older adult asthmatics in vitro;
specifically, diminished IL-5 stimulated eosinophil
derived neurotoxin (EDN) release and superoxide pro-
duction [14]. In this pilot study , we sought to compare
pro-inflammatory lipid mediator production, specifically
leukotrienes LTB4 and CysLT, both in vitro and in vivo in
young and older adult asthmatics. Identifying the inflam-
matory differences seen in older asthmatics may be
important for the diagnosis, improving the morbidity and
mortality, as well as determining optimal therapies of the
disease in this growing population.
Methods
We recruited subjects in two age groups, 20 to 40 years (n
= 12) and 50 to 70 years (n = 6), in a study protocol
approved by the University of Wisconsin Health Sciences
Institutional Review Board. Inclusion criteria included a
physician diagnosis of mild to moderate asthma with a
provocative concentration of methacholine causing a 20%
fall in FEV1 (PC20) of < 8 mg/mL or albuterol reversibility
on spirometry of ≥ 12%. Exclusion criteria included his-
tory of tobacco use > 5 pack-years or use in the previous
year, prednisone use within 1 month, donation of blood
(greater than 1/2 pint) in the previous 8 weeks, FEV1 <
60%, severe asthma, upper and/or lower respiratory tract
infection in the previous 4 weeks, diabetes, pregnancy, or
an active cardiovascular disease other than controlled
hypertension.
At the study visit, medical history, spirometry with
bronchodilator reversibility, sputum induction, allergy
skin prick test, physician exam and phlebotomy were per-
formed. Sputum processing was performed as described
previously [15]. LTB4, LTC4 and CysLT levels in culture
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supernates or the sputum samples were measured using
the LTB4, LTC4 and CysLT competitive EIA kits, respec-
tively (Cayman Chemical, Ann Arbor, MI). Heparinized
venous blood was lysed in a hypotonic solution and sub-
jected to gradient centrifugation. Neutrophils were iso-
lated from the granulocyte pellet and were > 95% pure
and > 98% viable. Eosinophils were also isolated from the
granulocyte pellet by negative selection using anti-CD16,
anti-CD14, and anti-CD3 magnetic beads (Miltenyi Bio-
technology; Auburn,CA) as described previously [16].
The eosinophils were typically > 99% pure and > 98% via-
ble.
Results
Table 1 shows a comparison of lung function and periph-
eral blood characteristics for the subjects in the study.
Both FEV1 and FVC were significantly lower in the older
group compared to the young subjects, which is consis-
tent with lung volume decreases in the aging population
[17]. However, percentage of predicted values, for both
FEV1  and FVC were comparable between young and
older groups, suggesting similar disease severity in both
age groups. There was no difference in peripheral blood
eosinophil counts between young and older asthmatics.
Sputum cell differentials revealed a tendency for
increased percentage of neutrophils in older asthma sub-
jects, 72(65-76)%, compared to young asthma subjects,
42(21-66)%, p = 0.09 (Figure 1A). This is consistent with
our previous cohort of older asthmatics exhibiting a sig-
nificantly higher percentage of sputum neutrophils [18].
The total number of eosinophils in the sputum were sim-
ilar in both the young and older group [Young: 0.6 (0-1.3)
× 10,000 cells/gm; Older: 0.5 (0.1-3.9) × 10,000 cells/gm;
Figure 1B], while the total numbers of neutrophils appar-
ently increased though not statistically significant
[Young: 30 (4-138) × 10,000 cells/gm; Older 68 (4-304) ×
10,000 cells/gm; Figure 1C].
In vivo levels of LTB4 and CysLT were measured in the
induced sputum samples from young and older asthma
subjects. Sputum LTB4 levels in older asthma subjects,
320 (301-397) pg/mL, were significantly decreased com-
pared to the young subjects, 1235 (706-2259) pg/mL, p =
0.015 (Figure 2A). Sputum CysLT levels in older asthma
subjects, 264 (224-269) pg/mL, were lower than in
younger asthma subjects, 717 (408-1152) pg/mL; how-
ever, this only approached statistical significance, p = 0.06
(Figure 2B).
In order to determine whether these in vivo differences
were due to an age-related diminished ability of neutro-
phils or eosinophils to produce leukotrienes, both puri-
Table 1: Subject Characteristics
Young (n = 12) Older (n = 6)
Age (years, range given)* 27 (20-35) 64 (58-70)
Duration of disease 17 (6-30) 37 (4-65)
FEV1 (L)* 3.35 (+/- 0.81) 2.24(+/- 0.28)
FEV1 % Predicted 86 (+/- 14.7) 81 (+/- 16.46)
FVC (L)* 4.28 (3.99-5.02) 3.24 (+/- 0.71)
FVC % Predicted 100 (+/- 12.15) 89 (+/- 12.62)
WBC (106cells/mL) 5.55 (4.75-6.85) 5.6 (5.13-6)
Absolute Eosinophil Count (cells/mL) 204 (+/- 127.75) 114 (+/- 82.95)
Positive Allergy Testing+ 11/12 6/6
Inhaled Corticosteroid Use 6/12 4/6
Data are presented as mean values (+/- standard deviation; t-test) or median values (25%-75% interval; Mann-Whitney Rank-Sum). 
*Statistically significant difference between young subjects and older subjects (p < 0.05). +At least one positive skin prick test result for grass, 
mold, ragweed, tree, cat, dog, or dust mite.Nyenhuis et al. Immunity & Ageing 2010, 7:8
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fied neutrophils and eosinophils were treated with
calcium ionophore to stimulate leukotriene production.
As shown in Figure 2C, the neutrophil production of
LTB4 from older asthma subjects, 8708 ± 5326 pg/mL,
was comparable to the young subjects, 10234 ± 3078 pg/
mL, p = 0.45. Eosinophil production of LTC4 from young,
5836 (3678-9512) pg/mL, and older asthma subjects,
4766 (2685-8456) pg/mL, was also similar in the two
groups, p = 0.78 (Figure 2D).
Since GM-CSF can stimulate leukotriene production by
neutrophils and eosinophils[11] and changes in GM-CSF
mediated signaling have been shown to occur in elderly
human subjects in vitro[19,20], we examined GM-CSF
production by peripheral blood mononuclear cells
(PBMCs) in the older and young asthma subjects. As
Figure 1 Sputum cell type differentials. Box plots of sputum cell percentages (1A) and total eosinophil (1B) and neutrophil (1C) number are shown 
for young subjects (white bars; n = 11), and older subjects (gray bars; n = 6). One young subject had > 80% epithelial cells in the sputum (indicating 
oral/salivary contamination) and was not included in the sputum differential. Comparisons between the young and older groups were performed 
with t test analysis or Mann-Whitney rank sum analysis. Statistical significance was defined at p < 0.05. Mac = macrophage; Eos = eosinophil; Neut = 
neutrophil; Lymph = lymphocyte; Median: ----- (solid)
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shown in Figure 3, GM-CSF production by unstimulated
PBMC was similar; however, LPS-stimulated PBMCs
from the older asthma subjects, 125 ± 118 pg/mL, pro-
duced significantly less GM-CSF than their younger
counterparts, 317 ± 136 pg/mL, p = 0.01.
Discussion
To our knowledge, a characterization of leukotriene levels
has not been previously performed in an older adult
asthma population. In this pilot study of young and older
mild-to-moderate asthmatics we found that older asthma
subjects had lower in vivo levels of LTB4 and CysLT in the
sputum at baseline disease. This difference in leukotriene
levels was not a reflection of fewer eosinophils and neu-
trophils in the airway as the total number of these cells in
the sputum were similar or greater in our older asthmatic
group. However, young and older asthma subjects pro-
duced comparable amounts of LTB4 and LTC4 in vitro
when neutrophils and eosinophils, respectively, were
stimulated with calcium ionophore. The observation that
LPS stimulation of PBMCs resulted in less GM-CSF pro-
duction in the older asthma subjects provides a potential
explanation for the age-related differences in sputum leu-
kotriene levels. Rather than an intrinsic defect in neutro-
phils and eosinophils, there may be less GM-CSF in the
airways of older asthmatics serving as a stimulant to pro-
duce leukotrienes. However, it is possible that other age-
related changes in the in vivo inflammatory milieu con-
tribute to the diminished levels of leukotrienes in the air-
way.
There are several limitations to this study including the
absence of a control non-asthmatic population, lack of
subjects >65 years old, and few total number of subjects
enrolled. Though multiple studies have consistently
revealed increases in leukotriene production in asthmatic
airways compared to controls, we cannot fully gauge the
Figure 2 In vivo and in vitro leukotriene levels. Comparisons between the young and older groups were performed with t test analysis or Mann-
Whitney rank sum analysis. Statistical significance was defined at p < 0.05. White bars: young subjects; Gray bars: older subjects Mean: - - -(dashed) 
Median: ----- (solid). 2A and 2B. Sputum was processed and LTB4 and CysLT levels were measured using the LTB4 and CysLT competitive EIA kit, re-
spectively (Cayman Chemical, Ann Arbor, MI). Sputolysin (Calbiochem) was added to all assay standards to represent an equivalent amount in the 
diluted sputum samples and run in duplicate. Standard curves for LTB4 and CysLT were performed both with and without Sputolysin to ensure an 
equivalent slope was obtained. Young: n = 11 (One young subject had > 80% epithelial cells in the sputum and was not included in the biochemical 
analysis.); Older: n = 6. 2C and 2D. Peripheral blood neutrophils and eosinophils were isolated and stimulated with calcium ionophore (A23187) for 
60 min at 37°C. LTB4 and LTC4 were measured by competitive EIA kit (Cayman Chemical, Ann Arbor, MI). Young: n = 12; Older: n = 6
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magnitude of our findings in the older asthmatic without
non-asthmatic older controls [21]. It is possible though
that our findings would have been more profound if we
had more subjects in an even older (> 65 years old) popu-
lation. Furthermore, as a pilot study, we had a limited
number of subjects enrolled in order to establish prelimi-
nary observations to serve as the focus of future studies.
Calcium ionophore is a potent activator of leukotriene
production in eosinophils and neutrophils. It is possible
that we were unable to detect small differences in leukot-
riene production in vitro with the use of such a potent
stimulator of leukotriene production. Therefore, a less
potent, physiologically-relevant stimulant (such as GM-
CSF) could reveal a difference in leukotriene production
in vitro.
The use of inhaled glucocorticoids by some subjects in
our study may represent a confounder as glucocorticoids
can have multiple effects such as a decrease in inflamma-
tory mediators and neutrophil apoptosis [22]. However,
glucocorticoids have not been shown to affect LTB4 for-
mation in vitro and in vivo [23]. Also, we performed a sta-
tistical analysis of paired young and older subjects that
were matched based on inhaled corticosteroid use, which
continued to show statistically significant differences in
the in vivo leukotriene levels (data not shown). Thus, the
use of inhaled glucocorticoids alone cannot explain our
findings.
The lower levels of CysLTs in the airways of older adults
may have an impact on the effectiveness of CysLT recep-
tor antagonists in the older population. Two studies to
date have examined the efficacy of the CysLT receptor
antagonists in an older adult population and concluded
that their effectiveness might be limited or altered in
older asthmatics [24,25]. Furthermore, the neutrophil
predominance found in the airway of older asthmatics
may actually represent a tendency for decreased respon-
siveness to glucocorticoids as has been observed in the
neutrophilic phenotype of severe asthma [26].
Our findings show that aging can result in changes in
the airway environment in asthmatics, specifically an
increase in airway neutrophils and decreases in both
LTB4 and CysLT levels at baseline. This characterization
of leukotrienes in older adult asthmatics reveals signifi-
cant differences that may have clinical relevance not only
in baseline asthma but also during an exacerbation of dis-
ease. Understanding the biological changes of airway
inflammation in the aging population will aid in the
development of future therapies and impact the increased
morbidity and mortality that is associated with this phe-
notype of asthma.
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Figure 3 Production of GM-CSF in PBMCs; Peripheral blood 
mononuclear cells (PBMCs) were either not stimulated or stimu-
lated with LPS (0.4 μg/mL) and supernatants analyzed by ELISA 
for GM-CSF. Comparisons between the young and older groups were 
performed with t test analysis. Statistical significance was defined at p 
< 0.05. White bars: young subjects (n = 12); Gray bars: older subjects (n 
= 6); Mean: - - - (dashed) Median: ----- (solid)
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